April 2026
Psilocybin
What April 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
In April 2026, research on psilocybin showed mixed results: meta-analyses of depression trials found large effect sizes but low certainty due to methodological issues like waitlist controls and unblinding, while preclinical studies demonstrated sustained anti-nociceptive effects in mice and enhanced fear extinction after stress. A key caveat is that the clinical evidence remains preliminary and context-dependent, with no robust Phase 3 confirmation.
Confidence in the evidence
Low-Moderate- Two meta-analyses (N=514 and N=606) found large pooled effects but with extreme heterogeneity (I²=79-97%) and low GRADE certainty due to risk of bias and publication bias.
- Multiple preclinical studies (mice, rats) consistently show positive effects on pain, fear extinction, and neural plasticity, but these are animal models with limited direct human translation.
- One scoping review found no coherent explanation for repressed memory recovery with psychedelics, indicating limited empirical support for some proposed mechanisms.
- The evidence base includes many small, open-label, or exploratory studies, and the only Phase 1 study of a second psilocybin experience had a small sample (n=13) without a control group.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials 2026 | meta-analysis | 514 | Supports | Psilocybin-assisted therapy showed a large pooled effect size for depression reduction (SMD=1.27), but GRADE certainty was low due to risk of bias, heterogeneity, and waitlist-inflated effects. |
| The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes 2026 | meta-analysis | 606 | No effect | The pooled standardized mean difference was not statistically significant (-0.79, p=0.63) with extreme heterogeneity (I²=96.9%), and effects were highly dependent on comparator type. |
| Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. 2026 | preclinical | Supports | A single dose of psilocybin produced sustained anti-nociceptive effects and potentiated gabapentin analgesia, representing the first preclinical evidence of a psychedelic priming pain networks for existing analgesics. | |
| Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed mice. 2026 | preclinical | Supports | Psilocybin increased dendritic spine density in frontal cortical neurons and facilitated fear extinction after chronic restraint stress, demonstrating effects in a translationally relevant stress model. | |
| "Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use Disorder. 2026 | observational | Supports | Following psilocybin administration with psychotherapy, significant reorganization of functional connectivity was observed within and between attentional, default mode, and salience networks, with greater methamphetamine reductions associated with recovery of functional connectivity. | |
| Effects of a single dose of psilocybin on diet-induced weight loss in obese mice. 2026 | preclinical | Supports | A single dose of psilocybin exacerbated diet-induced weight loss over four weeks when mice were switched to low-fat chow, primarily by modulating food intake without affecting energy expenditure. | |
| Psilocybin reshapes cortical inhibition through selective interneuron recruitment. 2026 | preclinical | Supports | Psilocybin reduced firing of somatostatin-expressing interneurons and increased activity of parvalbumin-expressing interneurons in the medial frontal cortex, acting via 5-HT1A receptors to reshape cortical inhibition. | |
| Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in rats 2026 | preclinical | 18 | Mixed | Pure psilocybin decreased conditioned place preference scores (aversive effects), while whole mushroom extract showed no significant preference changes; the extract also increased liver weight and lipid peroxidation in the heart. |
| Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats 2026 | preclinical | 18 | Unclear | The study evaluated the impact of pure psilocybin and Psilocybe cubensis extract on gut microbiota, but the abstract does not report specific results on microbiota changes. |
| Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations. 2026 | preclinical | No effect | Psilocybin pretreatment did not restore social preference deficits induced by methamphetamine-fentanyl withdrawal at the time point examined, though it bidirectionally altered CRHR1 expression in the mPFC depending on drug history. | |
| Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. 2026 | observational | 150 | Supports | State of Surrender, experiential acceptance, cognitive defusion, and present-moment awareness emerged as robust predictors of mystical experiences, underscoring the role of psychological flexibility. |
| Evaluating the evidence for repressed memory recovery in psychedelic contexts 2026 | review | Unclear | The scoping review found that the literature did not offer a coherent explanation for how psychedelics could recover repressed memories, and empirical support for proposed mechanisms was limited. | |
| The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings. 2026 | review | Supports | The review synthesized evidence that music amplifies emotional and cognitive effects of psychedelics through neurobiological mechanisms, showing promise for treating depression, PTSD, and addiction. | |
| Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations 2026 | observational | Unclear | This pooled analysis aimed to provide comprehensive cardiovascular safety data for psilocybin, but the abstract does not report specific results. | |
| Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders. 2026 | theoretical | Supports | The paper proposed Psilocybin-Assisted Schema Therapy (PAST) as a model where psilocybin-induced cognitive flexibility may enhance responsiveness to schema therapy for personality disorders. | |
| A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience 2026 | observational | 13 | Supports | A second experience of Group Retreat Psilocybin Therapy with an increased dose (35 mg, optional 10 mg booster) reduced HADS Total scores from 15.08 to 9.00 at Day +8, with improvements maintained through 24-week follow-up. |
| Psilocybin as an alternative to conventional treatments: A systematic review 2026 | review | Supports | This systematic review of controlled clinical trials (2020-2025) found psilocybin-assisted therapy to be a promising alternative for treatment-resistant depression and anxiety, but the abstract does not report specific effect sizes. | |
| Prevalence and Correlates of Past-Year Psilocybin Use in the United States. 2026 | observational | Unclear | This study examined prevalence and correlates of past-year psilocybin use in the US, but the abstract does not report specific results. | |
| Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study. 2026 | observational | 2306 | Unclear | This cross-sectional survey study developed a data fusion framework to estimate reasons for using specific psychedelic drugs, but the abstract does not report specific findings on psilocybin. |
| Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity 2026 | observational | Unclear | This study investigated sustained brain connectivity changes after low-to-moderate psilocybin doses, but the abstract does not report specific results. | |
| Investigating Psychedelic Tryptamines: Extraction and Quantification from Psilocybe Mushrooms 2026 | preclinical | Unclear | This study developed an extraction and quantification method for psilocin and psilocybin from mushrooms, but the abstract does not report specific quantitative results. | |
| Comparative Medico-Legal Frameworks for Psilocybin Regulation: A March 2026 Update 2026 | review | Unclear | This update consolidated recent statutory amendments and regulatory decisions for psilocybin medical use across multiple jurisdictions, but the abstract does not report specific clinical outcomes. | |
| One Substance, Multiple Legal Realities: Classification Cascades in the Psychedelic Medicine Transition 2026 | observational | Supports | The study documented a classification cascade for psilocybin, noting FDA Breakthrough Therapy Designation, 58.6% CAGR in psilocybin-depression research, and COMP360's consecutive Phase 3 successes (MADRS -3.6 and -3.8 vs placebo, both p<0.001). | |
| Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration 2026 | theoretical | Supports | This paper discussed therapeutic opportunities for psilocybin in inflammation-driven disorders of aging, from depression to neurodegeneration, but the abstract does not report specific empirical results. | |
| Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey 2026 | observational | 343 | Unclear | In this convenience sample, 52.6% reported lifetime psilocybin use; curiosity was the primary motivation, and significant explanatory factors included male gender and bisexual identity. |
Psilocybin-assisted therapy showed a large pooled effect size for depression reduction (SMD=1.27), but GRADE certainty was low due to risk of bias, heterogeneity, and waitlist-inflated effects.
meta-analysis Sample size: 514
The pooled standardized mean difference was not statistically significant (-0.79, p=0.63) with extreme heterogeneity (I²=96.9%), and effects were highly dependent on comparator type.
meta-analysis Sample size: 606
A single dose of psilocybin produced sustained anti-nociceptive effects and potentiated gabapentin analgesia, representing the first preclinical evidence of a psychedelic priming pain networks for existing analgesics.
preclinical
Psilocybin increased dendritic spine density in frontal cortical neurons and facilitated fear extinction after chronic restraint stress, demonstrating effects in a translationally relevant stress model.
preclinical
Following psilocybin administration with psychotherapy, significant reorganization of functional connectivity was observed within and between attentional, default mode, and salience networks, with greater methamphetamine reductions associated with recovery of functional connectivity.
observational
A single dose of psilocybin exacerbated diet-induced weight loss over four weeks when mice were switched to low-fat chow, primarily by modulating food intake without affecting energy expenditure.
preclinical
Psilocybin reduced firing of somatostatin-expressing interneurons and increased activity of parvalbumin-expressing interneurons in the medial frontal cortex, acting via 5-HT1A receptors to reshape cortical inhibition.
preclinical
Pure psilocybin decreased conditioned place preference scores (aversive effects), while whole mushroom extract showed no significant preference changes; the extract also increased liver weight and lipid peroxidation in the heart.
preclinical Sample size: 18
The study evaluated the impact of pure psilocybin and Psilocybe cubensis extract on gut microbiota, but the abstract does not report specific results on microbiota changes.
preclinical Sample size: 18
Psilocybin pretreatment did not restore social preference deficits induced by methamphetamine-fentanyl withdrawal at the time point examined, though it bidirectionally altered CRHR1 expression in the mPFC depending on drug history.
preclinical
State of Surrender, experiential acceptance, cognitive defusion, and present-moment awareness emerged as robust predictors of mystical experiences, underscoring the role of psychological flexibility.
observational Sample size: 150
The scoping review found that the literature did not offer a coherent explanation for how psychedelics could recover repressed memories, and empirical support for proposed mechanisms was limited.
review
The review synthesized evidence that music amplifies emotional and cognitive effects of psychedelics through neurobiological mechanisms, showing promise for treating depression, PTSD, and addiction.
review
This pooled analysis aimed to provide comprehensive cardiovascular safety data for psilocybin, but the abstract does not report specific results.
observational
The paper proposed Psilocybin-Assisted Schema Therapy (PAST) as a model where psilocybin-induced cognitive flexibility may enhance responsiveness to schema therapy for personality disorders.
theoretical
A second experience of Group Retreat Psilocybin Therapy with an increased dose (35 mg, optional 10 mg booster) reduced HADS Total scores from 15.08 to 9.00 at Day +8, with improvements maintained through 24-week follow-up.
observational Sample size: 13
This systematic review of controlled clinical trials (2020-2025) found psilocybin-assisted therapy to be a promising alternative for treatment-resistant depression and anxiety, but the abstract does not report specific effect sizes.
review
This study examined prevalence and correlates of past-year psilocybin use in the US, but the abstract does not report specific results.
observational
This cross-sectional survey study developed a data fusion framework to estimate reasons for using specific psychedelic drugs, but the abstract does not report specific findings on psilocybin.
observational Sample size: 2306
This study investigated sustained brain connectivity changes after low-to-moderate psilocybin doses, but the abstract does not report specific results.
observational
This study developed an extraction and quantification method for psilocin and psilocybin from mushrooms, but the abstract does not report specific quantitative results.
preclinical
This update consolidated recent statutory amendments and regulatory decisions for psilocybin medical use across multiple jurisdictions, but the abstract does not report specific clinical outcomes.
review
The study documented a classification cascade for psilocybin, noting FDA Breakthrough Therapy Designation, 58.6% CAGR in psilocybin-depression research, and COMP360's consecutive Phase 3 successes (MADRS -3.6 and -3.8 vs placebo, both p<0.001).
observational
This paper discussed therapeutic opportunities for psilocybin in inflammation-driven disorders of aging, from depression to neurodegeneration, but the abstract does not report specific empirical results.
theoretical
In this convenience sample, 52.6% reported lifetime psilocybin use; curiosity was the primary motivation, and significant explanatory factors included male gender and bisexual identity.
observational Sample size: 343
Points of agreement
- Multiple meta-analyses and reviews indicate that psilocybin-assisted therapy shows large effect sizes for depression, but these are heavily qualified by methodological limitations such as waitlist controls and unblinding.
- Preclinical studies consistently demonstrate that psilocybin promotes neural plasticity (e.g., dendritic spine growth) and can facilitate behavioral changes like fear extinction and weight loss in animal models.
- Several studies highlight the importance of psychological factors (e.g., surrender, acceptance) and contextual factors (e.g., music, therapy integration) in shaping psilocybin's effects.
Conflicts
- One meta-analysis (article_id 27150) found a large significant pooled effect for depression (SMD=1.27, p<0.001), while another (article_id 27871) found a non-significant pooled effect (-0.79, p=0.63), with the difference attributed to comparator type and heterogeneity.
- In rats, pure psilocybin produced aversive effects in conditioned place preference, while whole mushroom extract did not, suggesting divergent behavioral effects between the isolated compound and the natural extract.
Gaps
- Durability of effects: most clinical trials have short-term follow-up, and long-term outcomes beyond 24 weeks are rarely reported.
- Blinding integrity: subjective psychedelic effects compromise blinding in clinical trials, and no studies address this methodologically.
- Dose-response and session structure: the optimal number of sessions and dose for different conditions remain unclear, with one meta-analysis showing more sessions may attenuate benefit.
- Populations: most research focuses on depression; studies on personality disorders, older adults, and chronic pain are preclinical or theoretical with limited clinical data.
- Comparative effectiveness: few studies compare psilocybin directly to active treatments (e.g., SSRIs) rather than waitlist or placebo.